Form 4 for NVCR NovoCure Ltd
Accepted 2025-03-04 00:00:00 ET · period of report 2025-03-03 · accession 0001562180-25-001976 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-04 | 2025-03-03 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $18.54 | -2,527 | 143.7K | -2% | -$46.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-03-03 | S | D | 2,527 | $18.54 | 143,673 | D | — | — | (F1) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. (F2) On the transaction date, the reporting person sold 2,527 shares in multiple trades at prices ranging from $18.02 to $18.9918. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. |